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Disruption of sialic acid metabolism drives tumor growth
by augmenting CD8+ T cell apoptosis
Lenneke A.M. Cornelissen, Athanasios Blanas, Joost C. van der Horst, Laura Kruijssen, Anouk Zaal, Tom O’Toole,
Lieke Wiercx, Yvette van Kooyk and Sandra J. van Vliet
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam
Infection and Immunity Institute, Amsterdam, The Netherlands
Sialylated glycan structures are known for their immunomodulatory capacities and their contribution to tumor immune evasion.
However, the role of aberrant sialylation in colorectal cancer and the consequences of complete tumor desialylation on anti-
tumor immunity remain unstudied. Here, we report that CRISPR/Cas9-mediated knock out of the CMAS gene, encoding a key
enzyme in the sialylation pathway, in the mouse colorectal cancer MC38 cell line completely abrogated cell surface expression
of sialic acids (MC38-Sianull) and, unexpectedly, significantly increased in vivo tumor growth compared to the control
MC38-MOCK cells. This enhanced tumor growth of MC38-Sianull cells could be attributed to decreased CD8+ T cell frequencies
in the tumor microenvironment only, as immune cell frequencies in tumor-draining lymph nodes remained unaffected. In
addition, MC38-Sianull cells were able to induce CD8+ T cell apoptosis in an antigen-independent manner. Moreover, low CMAS
gene expression correlated with reduced recurrence-free survival in a human colorectal cancer cohort, supporting the clinical
relevance of our work. Together, these results demonstrate for the first time a detrimental effect of complete tumor
desialylation on colorectal cancer tumor growth, which greatly impacts the design of novel cancer therapeutics aimed at
altering the tumor glycosylation profile.
Introduction
A major focus of current cancer research is the elucidation of
immune evasion strategies employed by malignant cells within
the tumor microenvironment (TME). The TME contains a
wide variety of cells, including stromal, endothelial and
immune cell subsets. The type, density and localization of
immune cells within the TME are defined as the Immuno-
score, which can be used to predict clinical outcome.1,2 As
such, cytotoxic CD8+ T cells are capable of eliminating tumor
cells and are thus strongly associated with an improved prog-
nosis in many cancer types.3 Nevertheless, as cancers develop,
tumor cells acquire the capacity to escape CD8+ T cell-
mediated cytotoxicity through down-regulation of major
histocompatibility complex class I (MHC-I) molecules and
expression of immune checkpoint molecules. The transition of
immune surveillance to immune escape has been described as
the cancer immunoediting hypothesis.4 Although cancer
immunoediting has been widely studied, the contribution of
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cancer-specific glycan structures on immune evasion still
remains undefined.
Glycosylation is an enzymatic post-translational process
that mediates the attachment of carbohydrate structures to
proteins and lipids and functions in a wide range of biological
processes including protein folding, cell adhesion and cell sig-
naling.5 Compared to their non-malignant counterparts,
tumor cells generally harbor an aberrant glycosylation profile
of N-glycans, O-glycans and glycolipids structures that are all
known to influence cancer development.6,7 The cancer-related
glycosylation profile is often characterized by an enhanced
expression level of sialylated glycan structures.8 Sialic acids
(Sias) are a family of nine-carbon monosaccharides with
N-acetylneuraminic acid (Neu5Ac) as the most common
member. Sialylated glycan structures can be recognized by
Sialic acid-binding immunoglobulin-type lectins (Siglecs),
which are mainly expressed on granulocytes, monocytes,
antigen presenting cells and natural killer (NK) cells.9 It is gen-
erally accepted that Sias are able to skew immune responses
toward immune suppression, since most Siglec receptors con-
tain an immunoreceptor tyrosine-based inhibitory motif
(ITIM) in their cytoplasmic domain. As Sias, although in lower
levels, are also expressed on non-malignant cells, the current
dogma states that Sias act as a shield to prevent inappropriate
immune reactions against self-antigens. This dampening of
immunity by Sias, therefore, led to the concept that glycans
represent a self-associated molecular pattern (SAMP) recog-
nized by self-pattern recognition receptors.10
Indeed, numerous studies have evaluated the negative
immunoregulatory function of Sias. Targeting of mouse den-
dritic cells with Sias conjugated to ovalbumin (OVA) aug-
ments the differentiation of regulatory T cells both in vitro
and in vivo.11 Also, Siglec-7 present on NK cells inhibits NK
cell cytotoxic activity when stimulated with natural sialylated
ligands.12,13 Since tumor cells express enhanced levels of Sias,
these cells might exploit the sialylation machinery to suppress
anti-tumor immune responses. Reduced tumor growth as well
as enhanced effector T cell responses and diminished regula-
tory T cell frequencies were found in a mouse model of B16
melanoma wherein the tumor harbored decreased levels of
sialylation.14–16 Moreover, a subset of tumor-infiltrating T
cells upregulates Siglec-9, which dampens anti-cancer immu-
nity, thus facilitating immune escape by the tumor.17
The involvement of Sias in suppression of subsequent
immune responses, prompted new therapeutic strategies aimed
at reducing tumor-associated Sia expression to enhance anti-
tumor immunity. Xiao et al. developed an anti-HER2 antibody
and sialidase conjugate that simultaneously cleaves Sias from
the cell surface and targets tumor cells for antibody-dependent
cell-mediated cytotoxicity by NK cells.17,18 More recently, intra-
cellular Sia blockade was shown to be sufficient to enhance
CD8+ T cytotoxicity, resulting in reduced tumor burdens.16
While these new therapeutic approaches lower the Sia expres-
sion of tumors, the effect of complete tumor desialylation on
the anti-tumor immune response has never been investigated.
Moreover, glycosylation patterns differ substantially between
and within tumor types,19 urging the need to increase our
understanding on how tumor-associated glycan structures
influence the immune system in tumors of different origins.
With our study we are the first to explore the effect of com-
plete tumor desialylation in colorectal cancer (CRC). The adult
gastrointestinal tract is a heavily glycosylated area with distinct
regional differences, whereby sialic acid levels are higher in the
colon compared to the ileum.20–22 Also, recurrence of CRC
tumors is correlated with a distinct glycosylation profile, illus-
trating the relevance of tumor glycosylation in CRC specifi-
cally.23 We assessed tumor growth and the anti-tumor immune
response in vivo using CRISPR/Cas9 glyco-engineered MC38
CRC cells. Unexpectedly, desialylated MC38 (MC38-Sianull) cells
grew significantly faster in vivo, which we attribute to decreased
CD8+ frequencies present within the tumor microenvironment.
In addition, we found that MC38-Sianull cells were capable of
inducing CD8+ T cell apoptosis, likely explaining the reduced
CD8+ T cells frequencies in vivo. Collectively, these results
strongly argue that complete tumor desialylation may have detri-
mental effects on anti-tumor immunity, thus greatly impacting
the design of novel cancer therapeutics aimed at targeting the
tumor sialylation profile.
Materials and Methods
CRISPR/Cas9 constructs
CRISPR/Cas9 constructs were made as previously described.24
The following gRNA strands for murine CMAS were used:
CMAS #1: top strand CACCGAATGTGGCCAAACAGTT; bot-
tom strand CTTACACCGGTTTGTCAACAAA; and CMAS #2:
top strand CACCGTTTCAGAACTTCTTCGA; bottom strand:
CAAAGTCTTGAAGAAGCTCAAA. The gRNA strands were
phosphorylated and annealed prior to cloning in the pSpCas9
(BB)-2A-Puro plasmid, a gift from Feng Zhang (Addgene
#62988). Cloning mixtures were treated with PlasmidSafe
What’s new?
The current dogma that tumor cells express sialic acids to dampen anti-tumor immunity has led to the development of novel
therapeutic strategies aimed at dismantling sialic acid-induced tolerance. Yet the effect of a complete loss of tumor sialylation
remains to be elucidated. This study is the first to report a detrimental effect of complete tumor desialylation on colorectal
cancer tumor growth, which could be attributed to augmented CD8+ T cell apoptosis. The work revisits how tumor-associated
sialic acids influence the anti-tumor immune response and has implications for the design of novel cancer therapeutics aimed
at altering the tumor glycosylation profile.
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exonuclease (Epicentre) to digest residual linearized DNA and
used for transformation in XL1-Blue Sublconing-Grade compe-
tent bacteria (Stratagene). The Nucleobond Xtra Midi kit
(Macherey-Nagel) was used to purify the plasmids. Purified
constructs were stored at −20 C until further use.
Generation of the MC38-Sianull cell line
MC38 cells were cultured in DMEM supplemented with 10%
heat inactivated fetal calf serum (FCS, Biowest), 1% penicillin
and 1% streptomycin. Cells (70–90% confluency) were trans-
fected with CRISPR/Cas9 constructs (3 μg per 6-well) targeting
the CMAS gene (MC38-Sianull) or an empty CRISPR/Cas9 con-
struct (MC38-MOCK). Lipofectamine LTX with PLUS™ reagent
(ThermoFisher Scientific) was used for transfection and applied
according to the manufacturer’s protocol. After 24 h, fresh
medium containing 3 μg/mL puromycin was added for
selection.
Transfected MC38-Sianull cells were incubated with 5 μg/mL
biotinylated Sia-specific Maackia amurensis Lectin II (MAL-
II, Vector Laboratories) for 1 h on ice, washed with medium
and incubated with streptavidin-PE (Jackson ImmunoRe-
search) on ice. After 1 h cells were washed and sorted in bulk
on MAL-IIlow cells.
To obtain supernatant samples, MC38-MOCK or
MC38-Sianull cells were cultured overnight in 96-wells plates at
a cell density of 3 × 104 cells/200 μL per well. For heat inactiva-
tion, supernatant samples were incubated at 65 C for 5 min.
Surveyor assay
Genomic DNA was isolated with the Quick-DNA™ kit
(Zymo research) according to the manufacturer’s protocol.
PCR products (732 bp) for the CMAS gene (forward primer:
GGCCTGGGATTCAGGAACAT, reverse primer: TGCAGC
TGTACCCCAAGCA) were hybridized and treated with
Surveyor Nuclease (Surveyor® Mutation Detection Kit, Inte-
grated DNA Technologies) and loaded on a DNA agarose gel
to visualize presence or absence of the mutation.
Lectin flow cytometry
The biotinylated plant lectins Sambucus nigra agglutinin
(SNA, Vector Laboratories) and Maackia amurensis Lectin II
(MAL-II, Vector Laboratories) were used to detect α2-6 and
α2-3 Sias, respectively. MC38 cells were incubated with
5 μg/mL of the lectin for 30 min at 37 C. Cells were washed
and incubated with streptavidin-APC (BD Biosciences) for
30 min at 37 C. Cells were washed and acquired on the Beck-
man Coulter Cyan flow cytometer. Data was analyzed with
FlowJo v10.
N-glycan profiling using liquid chromatography mass-
spectrometry (LC–MS)
MC38-MOCK and MC38-Sianull cells were washed three times
with PBS and resuspended in 100 μL pure water, before
homogenization for 45 min in a sonication bath. Samples were
centrifuged (500g, 15 min) and 17.5 μL of pure water was
added. Five microliters of reaction buffer (250 mM sodium
phosphate buffer; pH 7.5) and 1.25 μL of denaturation buffer
(2% SDS in 1 M β-mercaptoethanol) were added. Samples
were incubated for 10 min at 100 C to denature the proteins,
afterwards 1.25 μL of Triton X-100 and 500 units of PNGase
F (QABio, California, USA) were added. Samples were vor-
texed and incubated overnight at 37 C. The released glycans
were then converted to aldoses with 0.1% formic acid, filtered
through a protein-binding membrane and dried.
Released N-glycans were fluorescently labeled by reductive
amination with procainamide as described previously25 using
the LudgerTagTM Procainamide Glycan Labelling Kit
(LT-KPROC-24). Procainamide labeled samples were analyzed
by HILIC-(U)HPLC-ESI-MS with fluorescence detection.
Samples were injected in 24% pure water/76% acetonitrile
onto an ACQUITY UPLC® BEH-Glycan 1.7 μm, 2.1 ×
150 mm column at 40 C on a Ultimate 3,000 UHPLC instru-
ment (Thermo Scientific, Massachusetts, USA) with a fluore-
sence detector (λex = 310 nm, λem = 370 nm). A glucose
homopolymer ladder labeled with procainamide (Ludger) was
used as a standard. ESI-MS and MS/MS data analysis was per-
formed using Bruker Compass DataAnalysis V4.1 software
and GlycoWorkbench software.26
CellTiter-blue® cell viability assay
The metabolic activity of MC38 cells was analyzed using the
CellTiter-Blue® Cell Viability assay (Promega) and measured
on the FLUOstar Galaxy (MTX Lab systems, excitation
560 nm, emission 590 nm).
In vivo tumor experiments
C57BL/6, NOD.Cg-Prkdcscid Il2rgrm1Wjl/SzJ (NSG, Charles
River) and OT-I mice were used at 8–12 weeks of age and
bred at the animal facilities of Amsterdam UMC. For all
in vivo experiments, an equal distribution of female and male
mice was used. Experiments were performed in accordance
with national and international guidelines and regulations.
Tumor cells (2 × 105 per mouse) were injected subcutane-
ously in the flanks. Tumors were measured three times per
week in a double-blind manner. Total tumor volume was cal-
culated using the formula 4/3 × π × abc (a = width of the
tumor/2, b = length/2 and c = the average of a and b). Mice
were sacrificed at day 13 after inoculation or when the tumor
reached a size of 2000 mm3. Tumor and tumor-draining
lymph nodes were isolated and used for further experiments.
Tumor and lymph node dissociation
Tumors were finely minced and enzymatically digested in
RPMI containing 1 mg/mL Collagenase type 4 (Worthington),
30 units/mL DNase I type II (Sigma-Aldrich) and 100 μg/mL
hyaluronidase type V (Sigma-Aldrich) for 25 min at 37 C.
Lymph nodes were digested with 2 U/mL Liberase TM
(Roche) enriched with 30 units/mL DNase I type II for
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10 min at 37 C. All cell suspensions were passed through a
70 μm cell strainer and washed with RPMI supplemented with
10% FCS, 1% penicillin, 1% streptomycin and 1% glutamax.
Lymph node digestions were washed twice and directly used
for subsequent experiments. Tumor digestion mixtures were
loaded on a Ficoll gradient to enrich for lymphocytes and to
remove dead cell debris.
Immune cell profiling
Cells were pretreated with 2.4G2 (anti-CD16/32) for 10 min at
RT and cell viability was measured using a fixable viability dye
(Zombie NIR, Biolegend), 2 μg/mL DAPI or 7-AAD
(Invitrogen). Cells were stained for 20 min at RT using the fol-
lowing markers: anti-CD45-PerCp (30-F11), anti-CD31-FITC
(390), anti-CD3-BV510 (17A2), anti-CD4-A700 (GK1.5), anti-
CD8b-FITC (YTS156.7.7), anti-PD-1-BV785 (29F.1A12), anti-
NK.1.1-PE/Dazzle 594 (PK136), anti-NKp46-BV421 (29A1.4)
(all from Biolegend) and anti-CD8b-APC (eBioH35-17.2,
eBioscience). To stain for Foxp3, cells were fixed and permeabi-
lized according to the manufacturer’s protocol (Foxp3 Tran-
scription Factor Staining buffer set, eBioscience) and incubated
with anti-Foxp3-PE antibodies (150D, Biolegend) for 20 min at
RT. For tetramer staining, fluorophore-conjugated MHC-I pep-
tide complexes were added to the cells prior to cell surface
staining. The Dpagt1-H-2Kb, Reps1-H-2Db and Adpgk-H-2Db
tetramers were obtained through the NIH Tetramer Core
Facility (Emory University, Atlanta) and labeled with PE, APC
and BV421, respectively. Samples were acquired on BD
LSRFortessa™ X-20. Data was analyzed with FlowJo v10.
Generation of activated OT-I CD8+ T cells
To obtain activated CD8+ OT-I T cells, an OT-I spleen was
minced and meshed through a 70 μm cell strainer. Cells were
cultured in RPMI supplemented with 10% heat inactivated
FCS, 1% penicillin, 1% streptomycin, 1% glutamax and 50 μM
2-Mercaptoethanol at a concentration of 3.5 × 106 splenocy-
tes/mL in presence of 0.75 μg/mL OVA257-264 peptide. After
3 days, 2 mL medium containing 10 U/mL rmIL-2 was added.
At day 5 of culture, CD8+ T cells were purified using
Lympholyte separation medium (Cedarlane) and checked for
purity by staining for CD8b (>90%).
T cell cytotoxicity assay
MC38-MOCK and MC38-Sianull cells were labeled with CFSE
(Thermofisher) and CellVue® Claret (Sigma) respectively,
according to the manufacturer’s protocol. After labeling, cells
were pulsed with the OVA257-264 peptide for 2 h at 37 C.
MC38-MOCK and MC38-Sianull cells were plated with or
without activated OT-I CD8+ T cells and after 5 h of incuba-
tion, cells were stained with anti-CD45 and DAPI and
acquired on BD LSRFortessa™ X-20. Data was analyzed with
FlowJo v10. Tumor cell viability was calculated by dividing
the number of viable MC38 cells incubated with CD8+ T cells
by the number of viable MC38 cells cultured without CD8+ T
cells x 100%.
CD8+ T cell apoptosis assays
Fresh C57BL/6 splenocytes or activated OT-I CD8+ T cells
were co-cultured with MC38-MOCK or MC38-Sianull cells or
supernatants as indicated. PHA-L (Vector Laboratories)
(2 μg/mL) was added to the C57BL/6 splenoctyes for activa-
tion. Cells were stained with anti-CD8b and 7-AAD and sub-
sequently with Annexin V-FITC (in Annexin V buffer, BD
Bioscience). Non-apoptotic CD8+ T cells were measured on
the BD LSRFortessa™ X-20 and analyzed with FlowJo v10.
Colorectal cancer cohort
Dataset GSE39582 was obtained from the Gene Expression
Omnibus (GEO, https://www.ncbi.nlm.nih.gov/gds).27 The
median of CMAS gene expression from 566 CRC patients was
ranked from low to high and divided into CMAShigh (median
gene expression >300) and CMASlow (<150) groups. Both
groups were used to analyze the recurrence-free survival.
Statistical analysis
Statistical significance was tested using GraphPad Prism by
performing an unpaired nonparametric t-test. Recurrence free
survival was displayed in Kaplan–Meier curves and statistical
significance was calculated by Log-rank Mantel-Cox test using
GraphPad Prism. (*p < 0.05, **p < 0.01, ***p < 0.001; ns, not
significant).
Results
Lack of cell surface Sia expression after CMAS gene
knockout
We first analyzed the mouse colorectal cancer cell line (MC38
wild type, MC38-WT) for the presence of sialic acids (Sias).
Sias, linked in an α2-6 or α2-3 configuration to the underlying
galactose residue, can be visualized using the plant lectins
Sambucus nigra agglutinin (SNA) and Maackia amurensis lec-
tin II (MAL-II), respectively. MC38-WT cells displayed high
binding of MAL-II, while SNA binding was negative (Fig. 1a),
indicating that MC38-WT cells only expressed α2-3 linked
Sias. In order to reduce Sia expression on the tumor cell sur-
face, we previously targeted the SLC35A1 Sia transporter using
shRNA, which resulted in decreased, but still detectable levels
of Sia15 (see Fig. 1b for an overview of the sialylation path-
way). However, SLC35A1 was recently shown to be involved
in the O-mannosylation pathway as well.28 Hence, for the pre-
sent study we mutated the N-acylneuraminate cytidylyltrans-
ferase (CMAS) gene, which catalyzes the activation of Neu5Ac
to 50-monophosphate N-acetylneuraminic acid (CMP-
Neu5Ac), the substrate required for the addition of Sia to the
growing glycan chain (Fig. 1b). We designed two different
CRISPR/Cas9 guideRNAs, targeting distinct regions in the
CMAS gene. Independent of the guideRNA used, both CMAS
knockouts (MC38-Sianull) displayed a complete lack of cell
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Figure 1. Cell surface sialic acid expression is abrogated in the CMAS gene knockout. (a) The presence of α2-6 and α2-3 Sia in MC38-WT cells
was assessed by flow cytometry using the plant lectins SNA and MAL-II, respectively. (b) Schematic representation of the sialylation pathway.
(c) Two CRISPR/Cas9 guideRNAs targeting distinct regions in the CMAS gene both completely abrogate MC38 sialylation (MC38-Sianull) as
measured with plant lectins SNA and MAL-II. MOCK-transfected MC38 cells (MC38-MOCK) were used as a negative control. Relative mean
fluorescence intensities (MFI) were calculated relative to MFI of the 2nd antibody only. Data are representative of three independent
experiments (a and c). Mean  SD; ***, p < 0.001. (d) Liquid Chromatography-Mass spectrometry (LC–MS) analysis of MC38-MOCK (upper)
and MC38-Sianull (bottom) sialylation. Only representative examples of the identified sialylated glycans structures are depicted. [Color figure
can be viewed at wileyonlinelibrary.com]
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surface Sia (Fig. 1c). The CMAS gene mutation was confirmed
using the Surveyor assay (Supporting Information Fig. 1A)
and by mass spectrometric analysis (Fig. 1d and Supporting
Information Table S1). We could only detect one minor sialy-
lated glycan structure on MC38-Sianull cells, which we assume
is a contamination from the MC38 culture medium.
Manipulation of the glycosylation machinery may influ-
ence the proliferation capacity of cells. Nevertheless,
MC38-MOCK and MC38-Sianull cells displayed identical
growth rates under in vitro culture conditions as observed by
manual counting and by measuring their metabolic activity
(Supporting Information Fig. 1B and C). Thus, we obtained a
completely desialyated non-clonal MC38 cell line through
CRISPR/Cas9 genome engineering of the CMAS gene.
MC38-Sianull cells display enhanced tumor growth in vivo
Next, we investigated the effect of complete tumor desialyla-
tion on in vivo tumor growth by injecting MC38-MOCK and
MC38-Sianull cells into C57Bl/6 mice (Fig. 2a). Unexpectedly,
the MC38-Sianull tumors grew significantly faster than
MC38-MOCK tumors (Figs. 2b and 2c). The tumor mass,
weighed directly after isolation, correlated to tumor size
(Supporting Information Fig. 2A), confirming the tumor mea-
surements were accurately performed. Moreover, the
MC38-Sianull cells retained their Sia negative phenotype after
in vivo passage (Supporting Information Fig. 2B).
To ascertain that the differences observed in tumor growth
were due to alterations in anti-tumor immunity, we inoculated
the MC38-MOCK and MC38-Sianull cells into immunodefi-
cient mice (NOD.Cg-Prkdcscid Il2rgrm1Wjl/SzJ, NSG mice). Com-
pared to immunocompetent mice, MC38-MOCK tumors grew
faster in immunodeficient mice, providing evidence for the
existence of immune surveillance toward the MC38-MOCK
tumors (Figs. 2b and 2d). In contrast, the MC38-Sianull only
displayed a small increase in tumor growth in the immunodefi-
cient mice compared to the immunocompetent mice (Figs. 2b
and 2d), suggesting in the case of MC38-Sianull, the immune
system is less able to recognize or can less efficiently combat
Figure 2. MC38-Sianull tumors display enhanced tumor growth in vivo. (a) MC38-MOCK or MC38-Sianull cells were injected into C57Bl/6 mice
(n = 14) and immunodeficient NOD.Cg-Prkdcscid Il2rgrm1Wjl/SzJ (NSG) mice (n = 9). (b–d) Tumor growth was monitored and depicted as mean
tumor size (b) or individual tumor growth curves (c and d). Data are representative of one (d) or three (c) independent experiments.
Mean  SEM; ***, p < 0.001; ns, not significant. [Color figure can be viewed at wileyonlinelibrary.com]
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MC38-Sianull tumor outgrowth. Together, our data imply that
complete CRC desialylation actually augments tumor growth,
which might be attributed to a lack of activation or a height-
ened suppression of anti-tumor immunity.
MC38-Sianull tumors harbor less CD8+ T cells
To explore whether tumor desialylation influences anti-tumor
immunity, we analyzed the immune cell composition of the
tumor and tumor-draining lymph nodes at day 13 of tumor
development (Fig. 3a). Compared to MC38-MOCK, the
MC38-Sianull tumors harbored less cytotoxic CD8+ T cells and
NK cells, while CD4+ T cells tended to be lower in
MC38-Sianull tumors (Fig. 3b). Strikingly, frequencies of
Foxp3+CD4+ regulatory T cells were equal in MC38-MOCK
and MC38-Sianull tumors (Fig. 3b). Moreover, the reduced
levels of CD8+ T cells and NK cells were only observed locally
at the tumor site, as the tumor-draining lymph nodes con-
tained equal frequencies of all subsets investigated (Supporting
Information Fig. 3A).
As MC38 tumors develop, CD8+ T cell frequencies seem to
drop.29 Thus, the decreased CD8+ T cell infiltration in
MC38-Sianull tumors might be explained by tumor size, which
Figure 3. MC38-Sianull tumors harbor less CD8+ T cells. MC38-MOCK or MC38-Sianull cells were injected in C57Bl/6 mice and sacrificed at day
13 of tumor development (a,b, n = 5) or when the tumor reached a size of 2000 mm3 (c–e, n = 9). (b) and (e) Flow cytometric analysis of
viable, CD45+ CD8+ T cells (CD3+CD8b+), CD4+ T cells (CD3+CD4+), Regulatory T cells (CD3+CD4+Foxp3+) and NK cells (CD3−NK1.1+) at tumor
site after 13 days of tumor development (b) or when the tumor reached a size of 2000 mm3 (e). Data are representative of two independent
experiments (a–e). Mean  SEM; *, p < 0.05; **, p < 0.01. [Color figure can be viewed at wileyonlinelibrary.com]
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at day 13 is significantly larger for MC38-Sianull, and not by
the desialylated phenotype (Supporting Information Fig. 4A).
Therefore, we also checked the immune composition when
tumors had an identical size of 2000 mm3 (Figs. 3c and 3d).
Interestingly, the reduced CD8+ T cell frequencies in the
MC38-Sianull were maintained in equally sized tumors (Fig. 3e).
In contrast to day 13 of tumor development, tumor-infiltrated
NK cell frequencies were similar in both MC38-MOCK and
MC38-Sianull tumors (Fig. 3e). Again, the levels of Foxp3+CD4+
regulatory T cells in the tumor (Fig. 3e) and the levels of CD8+,
CD4+, regulatory T and NK cells in the tumor-draining lymph
nodes remained unaffected (Supporting Information Fig. 3B).
Remarkably, also lower frequencies of PD-1+CD8+ T cells
were found in the MC38-Sianull tumors compared to the
MC38-MOCK tumors, both at day 13 of tumor development
(Fig. 4a) as well as when the tumors had an equal size
(Fig. 4b). This effect was solely observed at the tumor site and
not in the tumor draining lymph nodes (Figs. 4a and 4b). PD-
1 is well-known for its crucial role as a checkpoint molecule
in down-regulating immune responses.30 Nevertheless, PD-1
Figure 4. Less PD-1 positive and MC38 neoantigen-specifc CD8+ T cells at the MC38-Sianull tumor site. (a) and (b) Percentage of PD-1+CD8+
T cells was analyzed at the tumor location or in tumor-draining lymph nodes with flow cytometry at an early stage of tumor development (a)
or when the tumors reached an equal size (b). (c) Tumor infiltrated CD8+ T cells (viable CD45+CD3+CD8b+) were stained with tetramers
specific for three different MC38 neoantigens29 and analyzed by flow cytometry. Data are representative of two independent experiments.
Mean  SEM; *, p < 0.05; **, p < 0.01. [Color figure can be viewed at wileyonlinelibrary.com]
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expression is primarily induced upon TCR stimulation and
lost when T cells fail to receive sustained TCR signaling.31
Therefore, we checked whether the MC38-Sianull tumors also
contained less antigen-experienced tumor-specific CD8+
T cells. Yadav et al.29 identified three MC38-specific neoanti-
gens with a strong immunogenic potential. We tested the CD8+
T cell reactivity toward these neoantigens by generating tetra-
mers specific for these three identified neoantigens. Isolated
CD8+ T cells obtained from MC38-MOCK tumors indeed
displayed higher reactivity toward two of the neoantigens, while
the response to the third antigen showed a trend toward higher
recognition (Fig. 4c). The specificity of CD8+ T cells in the
tumor draining lymph node was indistinguishable between
MC38-MOCK and MC38-Sianull groups (Supporting Informa-
tion Fig. 4B). Together, these results indicate that the
MC38-MOCK tumors were infiltrated with more tumor-
specific CD8+ T cells than MC38-Sianull tumors, thus uncover-
ing a predominant effect of tumor desialylation on the CD8+ T
cell compartment exclusively in the tumor microenvironment.
MC38-Sianull tumors induce CD8+ T cell apoptosis
As the presence of CD8+ T cells in the tumor microenviron-
ment correlates with good prognosis,3 we hypothesized that
the enhanced growth of the MC38-Sianull tumors was due to
hampered elimination by cytotoxic CD8+ T cells. Moreover,
this appeared to be a local effect, as tumor-specific CD8+ T
cell frequencies were unaffected in tumor-draining lymph
nodes. To explore whether MC38-Sianull cells might be able to
suppress the cytotoxic function of CD8+ T-cells directly, we
performed a cytotoxicity assay using OT-I T cells and OVA-
loaded tumor cells as a model system. Activated OT-I CD8+ T
cells were co-cultured with OVA257-264 (SIINFEKL)-pulsed
MC38-MOCK and MC38-Sianull cells and assessed for tumor
cell eradication. To track the MC38 cells, MC38-MOCK cells
were labeled with CFSE and MC38-Sianull with CellVue©
Claret (Fig. 5a). After 5 h, OVA257-264-pulsed MC38-Sia
null
cells were less efficiently killed by the OT-I CD8+ T cells than
the MC38-MOCK cells (Fig. 5b), suggesting that upon
encounter of desialylated tumor cells, CD8+ T cells are func-
tionally inhibited in their cytotoxic response.
We next investigated whether MC38-Sianull cells are able to
influence CD8+ T cell function by provoking CD8+ T cell death.
Interestingly, fewer viable (7-AAD−Annexin V−) CD8+ T cells
could be recovered from 48 h co-cultures of wild type C57Bl/6
splenocytes with MC38-Sianull cells, than from splenocytes and
MC38-MOCK co-cultures (Fig. 5c). This effect seemed antigen-
independent, as it occurred both under medium conditions or
when T cells were further stimulated with PHA-L (Fig. 5c). To
mimic activated tumor-infiltrating CD8+ T cells, we employed
antigen-experienced OT-I T cells and investigated whether
MC38-Sianull also induced apoptosis of these CD8+ T cells with-
out accompanying antigen-specific stimulation. Indeed, at low
T cell-tumor ratios, MC38-Sianull cells induced 40% more CD8+
T cell apoptosis than MC38-MOCK cells (Fig. 5d).
We next assessed whether the MC38-Sianull-induced apopto-
sis was mediated by cell-intrinsic factors or via the secretion of a
soluble factor. Therefore, activated OT-I T cells were co-cultured
with MC38-MOCK cells in the presence or absence of superna-
tants derived from MC38-Sianull cells. Indeed, in the presence of
MC38-Sianull supernatant more CD8+ T cell apoptosis was mea-
sured, indicating that MC38-Sianull cells secrete a soluble pro-
apoptotic mediator (Fig. 5e). As the apoptosis induction
appeared to be antigen-independent and mediated by a soluble
factor in the MC38-Sianull supernatant, we questioned whether
MC38-Sianull supernatant alone might be sufficient to cause
CD8+ T cell apoptosis. To address this, we cultured CD8+ T cells
only in the presence of supernatants obtained from
MC38-MOCK or MC38-Sianull cells or plain medium as a nega-
tive control. As expected, CD8+ T cell apoptosis was increased
by 30% when cells were cultured in the presence of MC38-Sianull
supernatant instead of plain medium or MC38-MOCK superna-
tant (Fig. 5f ). To further characterize the apoptosis inducing fac-
tor secreted by MC38-Sianull cells, supernatants were heat
inactivated prior to addition to the CD8+ T cells. Heat inactiva-
tion of the MC38-Sianull supernatant completely abrogated CD8+
T cell apoptosis (Fig. 5g), suggesting that the MC38-Sianull-
specific apoptosis mediator is a heat-sensitive protein or peptide,
which acts in an antigen-independent manner.
Moreover, the augmented CD8+ T cell apoptosis could
provide an explanation for both the reduced CD8+ T cell fre-
quencies present in MC38-Sianull tumors as well as the dimin-
ished CD8+ T cell cytotoxicity toward MC38-Sianull cells
in vitro.
Low CMAS gene expression is associated with lower
recurrence-free survival
So far, our results indicate that loss of sialic acids might actually
be detrimental in CRC and thereby contradict other studies
investigating the role of tumor sialylation on the anti-tumor
immune response.15,16,32 To translate our findings to human
CRC patients, we analyzed CMAS gene expression in a human
colorectal cancer cohort (GSE39582) in relation to disease pro-
gression and survival. We stratified the CRC patients according
to their CMAS gene expression into two groups, CMAS low
(median <150, n = 74) or CMAS high (median >300, n = 81)
patients, and evaluated their recurrence-free survival. Interest-
ingly, low CMAS gene expression indeed correlated to a lower
recurrence-free survival in CRC patients (Fig. 6a), reflecting the
results obtained in our in vivo mouse studies. Thus, also in
human CRC patients, a low sialylation status of the tumor is
correlated to poor prognosis.
Partial tumor desialylation is sufficient to drive tumor
growth in CRC
Since low CMAS expression correlated to a lower recurrence-
free survival in CRC patients, we tried to mimic this in vivo
by investigating whether partial tumor desialylation would be
enough to sustain the enhanced tumor growth. Therefore, we
2298 Complete tumor desialylation drives tumor growth
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Figure 5. MC38-Sianull cells induce CD8+ T cell apoptosis. (a) and (b) MC38-MOCK and MC38-Sianull cells were pulsed with OVA257-264 and
labeled with CFSE or Cellvue Claret respectively (a). After 5 h of incubation with activated OT-I CD8+ T cells, viability of MC38 cells was
analyzed by flow cytometry and calculated by dividing the number of viable (7-AAD−Annexin V−) MC38 cells present in the CD8+ T cell co-
culture by the viable MC38 cells cultured without T cells and multiplied by 100% (b). (c–f ), Viable CD8+ T cells were analyzed with flow
cytometry and gated as CD8b+7-AAD−Annexin V−. (c) C, C57Bl/6 splenocytes were co-cultured with MC38-MOCK or MC38-Sianull cells in
presence of medium or PHA-L for 48 h. (d) Activated OT-I CD8+ T cells were co-cultured with MC38-MOCK or MC38-Sianull cells for 24 h.
(e) Activated OT-I CD8+ T cells were co-cultured with MC38-MOCK in presence of medium or MC38-Sianull supernatant for 24 h. (f ) and (g)
Activated OT-I CD8+ T cells were cultured with control (f ) or heat inactivated (g) medium, MC38-MOCK or MC38-Sianull supernatants for 24 h.
Data are representative of one (g), two (c, e and f ) or three (b and d) independent experiments. Bar, mean  SD; *, p < 0.05; **, p < 0.01;
***, p < 0.001; ns, not significant. [Color figure can be viewed at wileyonlinelibrary.com]
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inoculated mice with MC38-MOCK and MC38-Sianull cells in
a 30:70 ratio (MC38-MOCK/Sianull). Interestingly, the survival
curve of the mice injected with the mixed tumors followed the
survival curve of mice that received MC38-Sianull cells only
(Fig. 6b). Moreover, CD8+ T cell frequencies were decreased
to an equal level as in the MC38-Sianull tumors (Fig. 6c).
Together, these data imply that in CRC tumor growth is pro-
moted, even when only a proportion of the malignant cells in
the tumor microenvironment is completely desialylated.
Discussion
The upregulation of sialylated glycan structures on the cell
surface is a key feature of tumor cells, independent of the
tumor type. Sialylated structures are known to regulate
immune responses, whereby the current dogma states that
tumor cells exploit tumor-associated Sias to dampen anti-
tumor immunity.14–16 These findings have led to the develop-
ment of new therapeutic strategies aimed at reducing
tumor-associated Sia expression to dismantle the Sia-induced
tolerance. However, these novel therapeutic strategies may
result in a complete loss of tumor sialylation, yet the effect of
a total absence of sialylated structures on tumor growth and
anti-tumor immunity has not been investigated before.
Here, we report for the first time that complete abrogation
of Sias on the murine CRC cell line MC38 (MC38-Sianull) sig-
nificantly increased tumor growth in vivo. Noteworthy, the
MC38 CMAS mutated cells were selected in bulk and sorted
based on cell surface expression of Sias. In this way tumor
heterogeneity was maintained in our cell lines, allowing us to
exclude potential clonal effects. Intestinal mucins are known
to be both sialylated and/or sulphated,20 yet in the present
study we solely affected the sialylation pathway. Therefore, we
cannot exclude that sulphated glycans contribute to tumor
development in our model.
The increased tumor growth of MC38-Sianull cells could be
attributed to reduced CD8+ T cell frequencies present within
the tumor. Reduced migration of CD8+ T cells toward the
tumor core has been correlated with bad prognosis.2,33,34 As
we did not address the localization of the T cells within the
tumor microenvironment, we cannot rule out that CD8+
T cells were hampered in reaching the tumor core. Neverthe-
less, we did observe that CD8+ T cells displayed diminished
cytotoxicity and underwent apoptosis upon encounter of
MC38-Sianull cells. Thus, our study highlights that complete
tumor desialylation might be detrimental to the anti-tumor
immune response in CRC, which greatly complicates the
Figure 6. CMAS gene expression levels are correlated to recurrence-free survival in human colorectal cancer and a partial CMAS knock out is
sufficient to drive tumor growth in vivo. (a) CMAS gene expression data was analyzed in the GSE39582 colorectal cancer cohort.27 Patients
were stratified in two groups with either low CMAS gene expression (median < 150) or high CMAS gene expression (median > 300) and
evaluated for their recurrence-free survival. (b) MC38-MOCK, MC38-Sianull or MC38-MOCK cells (30%) mixed with MC38-Sianull cells (70%)
were injected into C57Bl/6 mice (n = 9) and sacrificed when the tumor reached a size of 2000 mm3. Tumor growth was measured and
survival curves of the mice are displayed. (c) Flow cytometric analysis of viable CD8+ T cells (CD3+CD8b+) at the tumor site when the tumor
reached a size of 2000 mm3. Mean  SD; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ns, not significant. [Color figure can be viewed at
wileyonlinelibrary.com]
2300 Complete tumor desialylation drives tumor growth
Int. J. Cancer: 144, 2290–2302 (2019) © 2018 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf
of UICC
T
um
or
Im
m
un
ol
og
y
an
d
M
ic
ro
en
vi
ro
n
m
en
t
design of novel cancer therapeutics aimed at targeting the
tumor glycosylation profile.
To abrogate cell surface sialylation we knocked out the
CMAS gene, a catalyzing enzyme involved in the sialylation
pathway, whereas other studies focused on the CMP-sialic acid
transporter, the SLC35A1 gene. Although both interrupt the sia-
lylation pathway, the consequences of this interruption might
significantly differ, since SLC35A1 has been described to be
involved in the O-mannosylation pathway as well.28 E-cadherin,
a protein well known for its role in epithelial-to-mesenchymal
transition and cancer metastasis,35 is O-mannosylated, which
is also crucial for E-cadherin-mediated cell adhesion. How-
ever, the choice of the target gene cannot fully explain the
observed discrepancies. Teoh et al.32 recently showed
decreased lung metastasis upon CMAS gene knock out in a
highly metastatic mammary cell line injected in BALB/c mice.
We, on the other hand, employed a non-metastatic CRC
model that was inoculated in C57BL/6 mice. The different
mouse strains, with their different predisposition toward T
helper 2 (Th2) and Th1 responses,36,37 as well as the different
tumor model used, may have impacted the outcome of the
respective studies. Discrepancies due to tumor type-specific
effects is further supported by the cohort data presented in
both studies32 (Fig. 6a). Our CRC cohort analysis revealed
that CMAS gene expression was positively correlated with
prognosis. Strikingly, only a proportion of MC38-Sianull cells
was sufficient to sustain the enhanced tumor growth in vivo.
The analysis of sialoglycans in CRC human tissues and their
link to CD8+ T cell tumor infiltration are subjects for future
studies.
Also in the B16 melanoma model, a reduction in tumor
sialylation (B16-Sialow) had a positive effect on the anti-tumor
immune response, resulting in decreased tumor growth.15,16
Interestingly, the B16 cell line expresses both α2-3 and
α2-6-linked Sias,15 while the MC38 cell line only carries
α2-3-linked Sias. This raises the possibility that our findings
might be related to the unique presence of α2-3-linked Sias or
conversely the absence of α2-6-linked Sias. Indeed, humans
generally express higher levels of α2-6-linked Sias than mice.38
Unfortunately, the different functions and roles of α2-3 and
α2-6-linked Sias and their cognate Siglec receptors in tumor
biology are hardly described in literature. In hepatocellular
carcinoma, Siglec-1+ macrophages negatively associate with
progression and predict favorable survival.39 Siglec-1 prefers
binding of α2-3-linked Sias over α2-6-linked Sias40 and lacks
the cytoplasmic ITIM domain, common in the majority of
Siglec receptors.41 Intriguingly, Siglec-1+ macrophages are able
to scavenge Sia+-particles from apoptotic tumor cells for sub-
sequent cross-presentation to tumor-specific CD8+ T cells.42,43
Thus, Siglec-1+ macrophages may actually have the potential
to propagate anti-tumor immunity.
In light of the lack of α2-6-linked Sias on our MC38 cells,
low and high levels of α2-6-linked Sias have indeed been cor-
related to tumor regression or progression, respectively.44
Especially, high expression of ST6Gal1, the enzyme responsi-
ble for α2-6-sialylation, has been associated with metastasis
and therapeutic failure in colorectal cancer specifically.45,46
ST6Gal1 modulates tumor differentiation in vivo via an
enhanced β1-integrin function that stimulates cell motility.46
These findings suggest that α2-6-linked Sias may be an impor-
tant instigator of Sia-mediated immune evasion in CRC. How-
ever, conclusive data is lacking to support this hypothesis and
should thus be further explored.
One soluble protein known to induce CD8+ T cell apopto-
sis is Galectin-1. Produced by tumor cells, Galectin-1 can bind
the Galβ1-4GlcNAc (LacNAc) epitope,47 which is elevated in
our MC38-Sianull cells after removal of the Sia. Galectin-1 sup-
ports tumor progression through cell–cell and cell-matrix
interactions as well as tumor-induced angiogenesis and an ele-
vated CD8+ T cell apoptosis.48 MC38-Sianull cells indeed
showed higher mRNA levels of the LGALS1 (Galectin-1) gene,
however, compared to MC38-MOCK, Galectin-1 protein con-
centrations in MC38-Sianull supernatants were not increased
(data not shown). Therefore, more research is required to
identify the soluble factor present in the MC38-Sianull
supernatant.
In conclusion, we have demonstrated that complete tumor
desialylation of the MC38 mouse CRC cell line augments
tumor growth and enhances CD8+ T cell apoptosis. Clearly,
discrepancies still exist regarding the expression levels or the
linkage type of α2-3 or α2-6 of Sias and the cellular origins of
the tumor. Therefore, the specific impact of α2-3 and
α2-6-linked Sias and their relative amounts on the anti-tumor
immune responses requires further research to fully under-
stand how various tumor types exploit the sialylation machin-
ery to evade anti-tumor immunity. Nevertheless, we argue
that in certain tumor types, for instance CRC, tumor sialyla-
tion may actually have a protective effect and we suggest that
therapies aimed at abrogating tumor-associated Sias should be
undertaken with caution.
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